244132-27-2

Usage

Uses

Used in Pharmaceutical Research:
(S)-1-(((9H-FLUOREN-9-YL)METHOXY)CARBONYL)-4-(TERT-BUTOXYCARBONYL)PIPERAZINE-2-CARBOXYLIC ACID is used as a research compound for the development of new pharmaceuticals due to its unique structure and functional groups, which may contribute to novel therapeutic agents.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, (S)-1-(((9H-FLUOREN-9-YL)METHOXY)CARBONYL)-4-(TERT-BUTOXYCARBONYL)PIPERAZINE-2-CARBOXYLIC ACID is utilized as a building block or intermediate in the synthesis of potential drug candidates, leveraging its functional groups for the creation of new molecules with therapeutic potential.
Used in Chemical Synthesis:
(S)-1-(((9H-FLUOREN-9-YL)METHOXY)CARBONYL)-4-(TERT-BUTOXYCARBONYL)PIPERAZINE-2-CARBOXYLIC ACID is employed as a reagent or intermediate in various chemical synthesis processes, taking advantage of its ability to donate a proton and its compatibility with other chemical entities.
Used in Biochemical Research:
In biochemical research, (S)-1-(((9H-FLUOREN-9-YL)METHOXY)CARBONYL)-4-(TERT-BUTOXYCARBONYL)PIPERAZINE-2-CARBOXYLIC ACID may be used to study interactions with biological molecules, such as enzymes or receptors, to understand its potential biological activity and applications in medicine.

Upstream product

• 28920-43-6 (fluorenylmethoxy)carbonyl chloride 
• 24424-99-5 di-tert-butyl dicarbonate 
• 848482-93-9 (S)-4-(tert-butoxycarbonyl)piperazine-2-carboxylic acid 

Downstream Products

• 1020840-80-5 C₄₃H₄₀ClN₅O₆ 

Relevant academic research and scientific papers

Solid-phase synthesis and biological evaluation of piperazine-based novel bacterial topoisomerase inhibitors

There is an emerging global need for new and more effective antibiotics against multi-resistant bacteria. This situation has led to massive industrial investigations on novel bacterial topoisomerase inhibitors (NBTIs) that target the vital bacterial enzym

Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions

The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.

Heterocyclic core analogs of a direct thrombin inhibitor

Thrombin is a serine protease that plays a key role in blood clotting. Pyrrolidine 1 is a potent thrombin inhibitor discovered at Merck several years ago. Seven analogs (2-8) of 1 in which the pyrrolidine core was replaced with various heterocycles were p

THROMBIN INHIBITORS

Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure: (I) or a pharmaceutically acceptable salt thereof, wherein Q is CH2, NR4, O, S, S(O) or S(O2

A traceless, solid-supported synthesis ofβ-turn mimetics based on the hexahydropyrazino[1,2-α ]pyrazine-1,2-dione scaffold

The solid-supported synthesis of a library of-turn mimetics based on the three-component Petasis condensation and 2,5-diketopiperazine formation is reported. The eight-step sequence starts from optically pure (S)-piperazine-2-carboxylic acid dihydrochloride, which is first converted into an orthogonally protected, resin-bound amino derivative. The subsequent transformations lead to compounds having the common hexahydropyrazino[1,2-a] pyrazine-1,2-dione core and diverse side chains, which mimic the-turn structure. This synthetic route includes protection of the initial amino acid with two different protecting groups, followed by attachment to the Wang resin using the Mitsunobu reaction, deprotection of the-nitrogen atom, then Petasis reaction, amidation, deprotection of the-nitrogen atom, coupling with a Boc-protected-amino acid, cleavage of the Boc group, and the cyclizative cleavage from the resin, resulting in the requested bicyclic products obtained in good yields and having good to moderate purities. Six different boronic acids, four amines, and nine-amino acids were applied to this synthetic route, to explore the efficiency and limitations of the described method. Georg Thieme Verlag Stuttgart.

A traceless solid-supported synthesis of novel pyrazinediazepinedione derivatives

A simple, convenient, six-step synthesis of novel, tricyclic pyrazinebenzodiazepinedione derivatives has been described. The strategy is based on the use of the orthogonally-protected, optically pure, (S)-piperazine-2-carboxylic acid, in a Petasis reaction, followed by coupling with anthranilic acid and finally cyclizing cleavage. The investigated method was applied for the synthesis of novel bicyclic pyrazinediazepinedione derivatives. This traceless, solid-supported approach allows the preparation of a wide variety of compounds in moderate yields from commercially available or easily obtainable reagents.

COMPOUNDS AND METHODS FOR TREATMENT OF HCV

Aryl substituted pyrazole derivatives are provided, as well as processes for their preparation. The invention also provides compositions and methods for the treatment of HCV by administering a compound of the present invention, alone or in combination with additional antiviral agents, in a therapeutically effective amount.